Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lessened its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 0.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,947,065 shares of the company’s stock after selling 18,484 shares during the quarter. Baillie Gifford & Co. owned 2.93% of Vir Biotechnology worth $39,984,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Rhumbline Advisers raised its holdings in Vir Biotechnology by 5.8% in the 3rd quarter. Rhumbline Advisers now owns 261,987 shares of the company’s stock worth $2,455,000 after purchasing an additional 14,374 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Vir Biotechnology by 99.9% during the third quarter. PNC Financial Services Group Inc. now owns 9,317 shares of the company’s stock valued at $87,000 after acquiring an additional 4,656 shares during the last quarter. Teza Capital Management LLC acquired a new position in shares of Vir Biotechnology during the third quarter valued at approximately $347,000. Schonfeld Strategic Advisors LLC raised its holdings in shares of Vir Biotechnology by 582.9% during the third quarter. Schonfeld Strategic Advisors LLC now owns 162,128 shares of the company’s stock valued at $1,519,000 after acquiring an additional 138,387 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Vir Biotechnology during the third quarter valued at approximately $1,098,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on VIR shares. Needham & Company LLC increased their target price on Vir Biotechnology from $15.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, June 5th. JPMorgan Chase & Co. upped their price target on Vir Biotechnology from $10.00 to $12.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Morgan Stanley upped their price target on Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Thursday, June 6th. Finally, HC Wainwright restated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research report on Wednesday, June 5th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.14.

Vir Biotechnology Trading Down 2.6 %

Vir Biotechnology stock traded down $0.23 during mid-day trading on Friday, hitting $8.53. The company’s stock had a trading volume of 614,724 shares, compared to its average volume of 1,446,215. Vir Biotechnology, Inc. has a 1 year low of $7.61 and a 1 year high of $24.46. The stock’s fifty day moving average is $9.84 and its two-hundred day moving average is $9.86.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.51. Vir Biotechnology had a negative return on equity of 32.58% and a negative net margin of 677.69%. The business had revenue of $56.38 million during the quarter, compared to analyst estimates of $11.71 million. During the same period last year, the business posted ($1.06) earnings per share. The company’s quarterly revenue was down 10.5% on a year-over-year basis. As a group, research analysts predict that Vir Biotechnology, Inc. will post -3.57 earnings per share for the current year.

Insider Transactions at Vir Biotechnology

In other news, Director Saira Ramasastry sold 4,000 shares of the stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $10.95, for a total value of $43,800.00. Following the sale, the director now directly owns 14,619 shares in the company, valued at $160,078.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 15.60% of the company’s stock.

Vir Biotechnology Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.